ITL limited (ASX:ITD) has advised that MyHealthTest has...

ITL limited (ASX:ITD) has advised that MyHealthTest has successfully launched its test to diagnose and monitor diabetes to coincide with the commencement of National Diabetes Week.

Its HbA1c test offers users the ability to collect samples in the convenience of their own homes.

Earlier this month, a research article published in the BMC Clinical Pathology Journal by researchers at the Australian National University John Curtin School of Medicine showed MHT’s Dried Blood Spots gave comparable results to venous collected whole blood samples.   

This follows on from the announcement in April that MHT had been awarded an Accelerating Commercialisation grant of up to $1 million from the Commonwealth Department of Industry and Science to fast-track the roll-out of its HbA1c test.

ITL has the exclusive opportunity to acquire up to 100% of MyHealthTest through a series of call options to be exercised subject to certain milestones being achieved.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.